Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Abbott Laboratories (NYSE:ABT) agreed to acquire Exact ...

Umama Ali spent more time as a kid arguing with his brother over who caused the most chaos in GTA Vice City than doing homework, and he’s been unapologetically hooked on games ever since. That ...

Exact Sciences stock now sits at the center of a tightening deal spread, with our fair value estimate holding steady near $103.67 per share. This closely tracks the proposed $105 takeout price even as ...

Abbott announced on Thursday, Nov. 20 it plans to buy Exact Sciences, a Madison-based maker of cancer screening and diagnostic tests, in a deal valued at an estimated $23 billion, including debt. The ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Abbott to buy Exact Sciences in $23 billion deal Exact's flagship colorectal cancer test to join Abbott's portfolio Abbott eyes international expansion for Exact's tests Aims for broad reimbursement ...

(RTTNews) - Abbott Laboratories (ABT) on Thursday said it has agreed to acquire Exact Sciences (EXAS) in a transaction worth an enterprise value of about $23 billion. Under the terms of the agreement, ...

Shares of Exact Sciences (EXAS) continued to rise in the premarket on Thursday, adding ~18% after the cancer test maker agreed to be acquired by Abbott Laboratories (ABT) in an all-cash deal worth ...

The cancer diagnostics specialist might, just might, be on the verge of selling itself. The apparent would-be buyer is a top name in the U.S. pharmaceutical industry. A strategic investor is ...